The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

The interconnected KIT receptor and Microphthalmia-associated transcription factor axis in melanoma

Author

Summary, in English

Melanoma is an aggressive disease that arises from deregulated signaling events in melanocytes. The KIT receptor tyrosine kinase and the Microphthalmia-associated transcription factor (MITF) are two essential components that are required for the normal physiology of melanocyte development and function. Consequently, aberrant activities of these factors are involved in the development of melanoma. To better

understand the molecular basis of disease development we studied the mechanisms that gatekeep and finetune the activity of both KIT and MITF.



In this thesis we have identified novel KIT ligand-dependent signaling pathways that, through MITF, affect cell proliferation. Notably, we found that the specific KIT tyrosine phosphorylation sites Y721 (PI3 kinase binding site), Y568 and Y570 (SRC binding sites) affect phosphorylation status of the MITF protein. Using

inhibitors against SRC, PI3K, AKT, MEK ERK and p38 during KIT activation, we identified that these signaling pathways are essential components in communicating signals between KIT and MITF.



The activity of KIT is regulated by the tetrapeptide insert in the extracellular juxtamembrane domain of the

receptor. By generating receptor mutants with different insert lengths, we showed that the length of this insert is critical for the fine tuning of receptor activation.



Using mass spectrometry and phospho-site specific antibodies against MITF, we found and characterized several serine and tyrosine phosphorylation sites in the protein. More importantly, in stark contrast to previous results, we discovered that the S73 and S409 phosphorylation sites of MITF are neither dependent

on KIT nor MAPK-ERK signaling. Furthermore, we show that the tyrosine phosphorylation sites of MITF are required for oncogenic KIT signaling and affect nuclear localization of MITF.



The structural properties of MITF and the KIT receptor were also clarified. By solving the crystal structure of MITF we explain the restricted heterodimerization of MITF towards TFEB, TFEC and TFE3, the binding of M-box DNA sequence and the ability to produce interallelic complementation.



In short, the detailing of KIT and MITF regulation has increased our understanding of key signaling

processes that are important to understand the development of melanoma.

Department/s

Publishing year

2013

Language

English

Publication/Series

Lund University Faculty of Medicine Doctoral Dissertation Series

Volume

2013:82

Document type

Dissertation

Publisher

Experimental Clinical Chemistry

Topic

  • Medicinal Chemistry

Status

Published

Supervisor

ISBN/ISSN/Other

  • ISSN: 1652-8220
  • ISBN: 978-91-87449-54-3

Defence date

6 September 2013

Defence time

13:15

Defence place

Clinical Research Centre lecture hall, Malmö

Opponent

  • Arne Östman (Professor)